Ivosidenib
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Ivosidenib: From IDH1-Mutant AML to Bulbar Polio
One-Sentence Summary
Ivosidenib (DB14568) is a mutant IDH1 (isocitrate dehydrogenase 1) inhibitor whose established global indication is IDH1-mutant acute myeloid leukemia (AML); this specific indication data point is not yet populated in the local regulatory dataset. The TxGNN model's top-ranked prediction is Bulbar Polio, but the evidence pack itself flags this as a likely false positive with no biological rationale. Zero clinical trials and zero publications currently support this direction — the model's embedding similarity does not translate into a plausible mechanism.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in local licenses; known global indication is IDH1-mutant Acute Myeloid Leukemia (per drug class/label information, not locally verified) |
| Predicted New Indication | Bulbar Polio |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L5 |
| Germany Market Status | 未上市 (Not Marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the evidence pack (flagged as a High-severity data gap, DG002). Based on the repurposing rationale accompanying the prediction, Ivosidenib is a selective inhibitor of mutant IDH1, blocking production of the oncometabolite 2-hydroxyglutarate (2-HG) — a metabolic/epigenetic pathway relevant to hematologic malignancy, not to neurological or infectious disease.
This top-ranked prediction is not mechanistically reasonable. Bulbar polio is a neurodegenerative condition caused by poliovirus infection of motor neurons. It shares no known pathway, target, or biological process with mutant-IDH1-driven oncogenesis. The evidence pack itself explicitly characterizes this as an embedding-similarity artifact ("false positive") with no supporting hypothesis — this is a case where a high TxGNN score does not indicate biological plausibility.
Two lower-ranked but more credible candidates exist in this evidence pack: AML/MDS related to prior radiation therapy and AML/MDS related to prior alkylating-agent therapy (both L4, "Research Question" stage). Both are therapy-related secondary leukemias that can, in a genotype-stratified subset, carry IDH1 R132 mutations analogous to Ivosidenib's approved primary-AML indication. However, TP53 mutation and complex karyotype — not IDH1 mutation — dominate these secondary leukemia subtypes, and no dedicated trials or case reports currently exist for this population. These remain hypothesis-generating extrapolations from the approved AML label rather than independently supported new indications.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Germany Market Information
No marketing authorizations are currently registered for this drug in the local dataset (market status: 未上市 / Not Marketed; total authorizations: 0).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (mutant IDH1 enzyme inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information. (No warnings, contraindications, or drug-interaction data are currently available; TFDA label data is flagged as a Blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Bulbar Polio) has no supporting mechanism, trials, or literature, and is explicitly identified within the evidence pack as a probable false positive. The two mechanistically plausible secondary candidates (therapy-related AML/MDS) remain at the Research Question stage (L4) with no direct clinical evidence, so no candidate in this pack currently justifies advancing beyond Hold.
To proceed, the following is needed:
- TFDA/manufacturer label data (warnings, contraindications) to close the Blocking data gap (DG001)
- Confirmed MOA data from DrugBank (DG002) to support formal mechanistic-link scoring
- If pursuing the AML/MDS-related candidates: genotype-stratified case series or registry data confirming IDH1 R132 mutation prevalence in radiation- and alkylating-agent-related secondary AML/MDS
- Targeted literature search restricted to therapy-related AML/MDS with IDH1 mutation status, rather than relying on primary-AML label extrapolation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.